Vaginal Estrogen: An Underutilized Tool for Preventing Recurrent Urinary Tract Infections in Postmenopausal Women

A Practical Guide for Hospice and Palliative Care Providers

“Sometimes the best palliative intervention isn’t another medication for symptoms—it’s restoring normal physiology.”

Introduction

Few problems frustrate hospice and palliative care teams more than the patient who develops “another UTI.”

The story is familiar.

An 84-year-old woman with advanced heart failure develops urinary urgency and burning. A urine culture grows Escherichia coli. She receives antibiotics and improves. Six weeks later, another UTI develops. Two months later, she is prescribed another antibiotic. Soon she has received multiple courses of cephalexin, nitrofurantoin, trimethoprim-sulfamethoxazole, or ciprofloxacin. Eventually, resistant organisms emerge, Clostridioides difficile becomes a concern, or she develops medication-related adverse effects.

For many of these women, the underlying problem is not a deficiency of antibiotics—it is a deficiency of estrogen.

Among postmenopausal women, hypoestrogenism fundamentally alters the urinary and vaginal environment, increasing susceptibility to recurrent urinary tract infections. Unlike repeated antibiotic therapy, low-dose vaginal estrogen addresses the underlying pathophysiology and has become one of the most evidence-supported non-antibiotic interventions for preventing recurrent UTIs.

For hospice and palliative clinicians whose goals center on comfort, reducing burdensome interventions, and preserving quality of life, vaginal estrogen deserves a place in routine clinical practice.

Why Are UTIs So Common After Menopause?

Before menopause, estrogen maintains a remarkably effective defense system within the lower urinary tract.

Healthy estrogen levels promote:

• Thick, resilient vaginal epithelium
• Adequate glycogen production
• Growth of protective Lactobacillus species
• Acidic vaginal pH (approximately 3.5–4.5)
• Reduced colonization by pathogenic bacteria
• Healthy urethral mucosa
• Enhanced local immune function

These mechanisms create a biologic barrier against ascending urinary pathogens.

Following menopause, estrogen levels decline dramatically. The consequences extend far beyond vaginal dryness.

The vaginal epithelium becomes thin and fragile. Glycogen production decreases. Lactobacilli disappear, and vaginal pH rises. Opportunistic bacteria—including E. coli—readily colonize the perineum and distal urethra.

Collectively, these changes are now recognized as part of Genitourinary Syndrome of Menopause (GSM). Although vaginal dryness receives much of the attention, recurrent urinary tract infections are among the syndrome’s most clinically important consequences.

The Microbiome Matters

One of the most fascinating discoveries over the past decade has been the importance of the vaginal microbiome.

Healthy vaginal flora are typically dominated by Lactobacillus species.

These organisms produce:

• Lactic acid
• Hydrogen peroxide
• Bacteriocins

Together they suppress the growth of pathogenic bacteria. Without estrogen, Lactobacillus populations diminish dramatically. The vaginal environment shifts from one dominated by protective organisms to one increasingly colonized by Enterobacteriaceae, particularly E. coli.

Repeated antibiotic exposure worsens this imbalance.

Ironically, each course of antibiotics intended to eliminate urinary pathogens may further disrupt the microbiome, setting the stage for the next infection.

Vaginal estrogen interrupts this cycle by restoring the environment that allows protective bacteria to flourish.

Why This Matters in Hospice

Hospice clinicians often encounter patients experiencing:

• Three or more UTIs annually
• Multiple emergency department visits
• Delirium associated with infections
• Falls precipitated by acute illness
• Progressive antimicrobial resistance
• Family requests for “another antibiotic”

Each episode carries consequences.

Antibiotics may produce:

• Nausea
• Diarrhea
• Drug interactions
• QT prolongation
• Clostridioides difficile infection
• Multidrug-resistant organisms

In patients with advanced illness, these complications may cause more suffering than the infection itself. Preventing recurrent infections aligns closely with the philosophy of palliative care.

Vaginal Estrogen Restores Physiology Rather Than Fighting Bacteria

Unlike antibiotics, vaginal estrogen is not antimicrobial. Instead, it restores normal anatomy and physiology.

Treatment results in:

• Thickening of vaginal epithelium
• Increased glycogen production
• Restoration of Lactobacillus dominance
• Lower vaginal pH
• Improved urethral mucosal integrity
• Reduced bacterial adherence
• Improved local immune defense

Rather than repeatedly killing bacteria, estrogen changes the environment so pathogenic bacteria are less likely to establish infection.

What Does the Evidence Show?

The evidence supporting vaginal estrogen is robust.

Randomized controlled trials consistently demonstrate significant reductions in recurrent urinary tract infections among postmenopausal women.

The landmark study by Raz and Stamm showed a dramatic reduction in infection frequency among women receiving intravaginal estriol compared with placebo.

Subsequent systematic reviews and meta-analyses have confirmed:

• Approximately 40–75% reduction in recurrent UTIs
• Longer intervals between infections
• Reduced antibiotic utilization
• Improved urinary symptoms
• Improved vaginal symptoms
• Better quality of life

Importantly, these benefits occur without contributing to antimicrobial resistance.

Additional Benefits Beyond UTI Prevention

Hospice clinicians frequently observe symptoms that patients may never volunteer.

Many older women silently experience:

• Vaginal dryness
• Burning
• Dyspareunia
• Pruritus
• Urinary urgency
• Frequency
• Mild stress incontinence
• Dysuria despite negative cultures

These symptoms often improve substantially with vaginal estrogen.

Patients frequently report:

“I don’t feel irritated anymore.”

“I’m sleeping because I’m not getting up every hour.”

“It doesn’t burn anymore.”

Sometimes the greatest benefit is simply reducing chronic discomfort that had become accepted as “part of aging.”

Choosing a Vaginal Estrogen Formulation

Several formulations are effective, and the choice should be individualized based on patient preference, dexterity, caregiver support, and cost.

Estradiol 0.01% vaginal cream is widely used because it is inexpensive, flexible in dosing, and treats both urinary and vulvovaginal symptoms. A common regimen is 0.5 g intravaginally nightly for two weeks, followed by 0.5 g twice weekly.

Conjugated estrogen cream is another effective option but may cause slightly more local irritation in some patients.

Estradiol vaginal tablets (10 mcg) are less messy and easier for many patients or caregivers to administer. They are typically inserted daily for two weeks and then twice weekly.

Estradiol vaginal rings release low-dose estrogen continuously for approximately three months. These are particularly helpful for patients with cognitive impairment or when adherence to a twice-weekly regimen is difficult.

No single formulation has consistently demonstrated superiority for preventing recurrent UTIs; selection should be based on patient preference, comfort, and practicality.

When Should Hospice Clinicians Consider Vaginal Estrogen?

The best candidates include postmenopausal women who have:

• Recurrent culture-confirmed UTIs
• Symptoms of genitourinary syndrome of menopause
• Frequent antibiotic exposure
• Recurrent catheter-associated irritation after catheter removal
• Dysuria with recurrent negative cultures suggestive of atrophic changes
• Recurrent delirium triggered by UTIs
• Multiple hospitalizations related to urinary infections

Even women with limited life expectancy may benefit if recurrent infections are contributing substantially to symptom burden or repeated antibiotic use.

Counseling Patients and Families

Education is essential for success.

Patients should understand:

• Vaginal estrogen is not an antibiotic.
• It will not treat an active infection.
• Benefits develop gradually over 6–12 weeks.
• Continued use is generally necessary to maintain effectiveness.
• Local irritation or mild spotting may occur initially but usually resolves.

Setting realistic expectations improves adherence.

Is Vaginal Estrogen Safe?

One of the greatest misconceptions is that vaginal estrogen carries the same risks as systemic hormone replacement therapy.

Fortunately, this is not the case.

Low-dose vaginal estrogen produces minimal systemic absorption.

Large observational studies have not demonstrated meaningful increases in:

• Stroke
• Venous thromboembolism
• Myocardial infarction
• Endometrial cancer when used at recommended doses
• Breast cancer recurrence in the general population

For women with estrogen receptor-positive breast cancer—particularly those receiving aromatase inhibitors—shared decision-making with the oncology team is recommended before initiating therapy.

For most hospice patients without these contraindications, low-dose vaginal estrogen is considered a low-risk intervention.

Practical Pearls for Hospice Nurses

Hospice nurses are often the first to identify women who could benefit from vaginal estrogen. Consider the possibility of genitourinary syndrome of menopause in postmenopausal women with recurrent urinary symptoms or repeated antibiotic courses. Distinguish dysuria caused by atrophic changes from infection by assessing for fever, systemic symptoms, and obtaining urine studies only when clinically appropriate. Teach patients and caregivers that symptom relief and infection prevention take time, typically requiring several weeks of therapy, and emphasize that ongoing treatment is needed to maintain the benefits. Monitor for mild local irritation or spotting during the initial weeks, and coordinate with the hospice physician if symptoms persist or contraindications arise.

Beyond Antibiotics: Supporting Antimicrobial Stewardship

Hospice and palliative care increasingly emphasize antimicrobial stewardship. Not every episode of bacteriuria requires antibiotics, particularly in frail older adults where asymptomatic bacteriuria is common. Vaginal estrogen complements stewardship efforts by reducing the frequency of symptomatic infections, decreasing antibiotic exposure, and helping preserve the effectiveness of antimicrobials for situations in which they are truly needed. This approach can reduce medication burden while supporting patient comfort and quality of life.

A Clinical Case

Mrs. H is an 88-year-old woman with advanced dementia receiving hospice care. Over the preceding year, she experienced five symptomatic E. coli UTIs, each treated with antibiotics. Her daughter noticed that every infection resulted in worsening confusion, decreased oral intake, and profound fatigue. The patient also had chronic vaginal dryness and urinary urgency but rarely mentioned these symptoms.

After discussing goals of care, the hospice team initiated low-dose estradiol vaginal cream. Over the following six months, she remained free of symptomatic UTIs, required no additional antibiotic courses, and her daughter reported that she appeared more comfortable and was sleeping through the night with fewer episodes of urinary urgency. While individual outcomes vary, this case illustrates how addressing the underlying hypoestrogenic state can reduce symptom burden and align with comfort-focused care.

The Bottom Line

For hospice and palliative care providers, recurrent urinary tract infections are more than an infectious disease problem—they are a source of pain, delirium, caregiver distress, repeated antibiotic exposure, and avoidable healthcare utilization. Low-dose vaginal estrogen offers a practical, evidence-based, non-antibiotic strategy that addresses the underlying physiologic changes of menopause rather than repeatedly treating their consequences.

By restoring the vaginal microbiome, improving mucosal health, and reducing susceptibility to bacterial colonization, vaginal estrogen can decrease recurrent infections while improving comfort, urinary symptoms, and quality of life. Although it will not replace antibiotics for active infection, it can reduce the need for them over time and supports the broader goals of hospice and palliative medicine: minimizing burdensome interventions, preventing avoidable complications, and helping patients live their remaining time with greater comfort and dignity.

References

American Geriatrics Society Beers Criteria® Update Expert Panel (2023) ‘American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults’, Journal of the American Geriatrics Society, 71(7), pp. 2052–2081.

American Urological Association (2022) Recurrent Uncomplicated Urinary Tract Infections in Women: Clinical Practice Guideline. Linthicum, MD: American Urological Association.

North American Menopause Society (2022) ‘The 2022 Hormone Therapy Position Statement of The North American Menopause Society’, Menopause, 29(7), pp. 767–794.

Perrotta, C., Aznar, M., Mejia, R., Albert, X. and Ng, C.W. (2008) ‘Oestrogens for preventing recurrent urinary tract infection in postmenopausal women’, Cochrane Database of Systematic Reviews, (2), CD005131.

Raz, R. and Stamm, W.E. (1993) ‘A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections’, New England Journal of Medicine, 329(11), pp. 753–756.

The American College of Obstetricians and Gynecologists (2021) Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer. Clinical Consensus No. 2. Washington, DC: ACOG.